Ho Wah Genting Bhd, which has jumped on the Covid-19 bandwagon, is considering appointing Xinkexian (Beijing) Biotechnology Co, Ltd (XKX) as its nonexclusive manufacturer to produce Covid-19 vaccines. Its wholly-owned subsidiary HWGB Biotech Sdn Bhd has entered into a Memorandum of Understanding with Xinkexian (Beijing) Biotechnology Co, Ltd (XKX) for a possible partnership. (The Edge)
"High percentage of retailer who think they can out-smart the stock market and enter lose making penny stock and dream to become a millionaire, majority will lose big amount of money compare to the retailer who put money on profit making company that its share price Rm1 and above counter"
Want to go vaccine counter? go to genuine vaccine counter example Pharmaniaga and Duopharma. Malaysia gave licence only to Pharmaniaga and Duopharma to distribute covid19. Dont act smart and think counter like Bintai,Hwgb,Mqtech etc can sell vaccine it will never happen in Million years in Malaysia. Never touch any lose making penny stock counter who try to ride on vaccine theme.
Want to invest on glove counter? invest only on genuine glove counter Top glove, Supermax, Hartalega, Kossan, Ruberex, Comfort, Careplus, Hlt and LKL.
Retailer need to be smart now and dont let syndicate pull your leg.
don't worry be happy.just follow director buying...maybe lose company making profit company future hahaha..many people say don't buy.but price still stabil and up....come to me rm2 baby.kahkahkah.
Yes agreed with menort. But if we flash back last time glove counter such as HLT, Care+, LKL, etc also like penny stock. If u realise currently all that counter be the selected and famous counter. Same goes to vaccine counter later on.. as long as make money.
Aduhai...kesal jual hari Jumaat lalu @0.72...huhuhu Besok kalau operator bagi jual sama gua pada limit-up @1.02 pun kira nasib lah...sudah terbulus baharu melantai!!!
HWGB WILL BENEFIT ENORMOUSLY FROM EBI'S RECENT “PHASE IV” CLINICAL TRIAL. THIS HAS PLACED EBI AHEAD OF ITS COMPETITORS WHICH ARE NOW AT “PHASE III” ONLY.
On 13th Sept 2020, EBI has engaged the services of Roderick A. Comunale II MD Inc (Principal Investigator) to conduct a clinical research study entitled “Inactivated Polio Vaccine in prevention of COVID-19 in high risk population in a Phase IV study, which shall study the effects of Inactive Polio Vaccine-IPV which shall be conducted according to the US Food and Drug Administration approved protocol and to be provided by EBI.
1) COVID-19 VACCINE TRACKER Globally, researchers are testing 40 vaccines in clinical trials on humans, and at least 92 preclinical vaccines are under active investigation in animals.
China is conducting clinical trials of 11 COVID-19 vaccines, 4 of which have entered Phase III trials, said Wang Zhigang, Chinese minister of Science and Technology, at the Global Science and Life Health Forum in Beijing on Friday (18th Sept 2020).
2) UNDERSTANDING THE 5 PHASES OF CLINICAL TRIALS https://en.m.wikipedia.org/wiki/Clinical_trial#Phases Clinical trials involving new drugs are commonly classified into five phases. Each phase of the drug approval process is treated as a separate clinical trial. The drug development process will normally proceed through phases I to IV over many years, frequently involving a decade or longer. If the drug successfully passes through phases I, II, and III, it will usually be approved by the national regulatory authority for use in the general population.
Phase IV trials are performed after the newly approved drug, diagnostic or device is marketed, providing assessment about risks, benefits, or best uses. ---> This refers to EBI’s Phase IV study;
3) UNDERTANDING THE TECHNICAL ROUTE FOR VACCINE DEVELOPMENT Vaccine development usually adopts five technical routes worldwide, namely inactivated vaccines, recombinant protein vaccines, attenuated influenza virus vaccines, adenoviral vector vaccines, and nucleic acid vaccines (mRNA, DNA).
(i) The inactivated vaccine is the most common approach. Its features are simple, rapid development, high safety, and usually used to deal with acute diseases. ---> This refers to EBI’s “Inactivated Polio Vaccine in prevention of COVID-19 in high risk population in a Phase IV study;
(ii) Adenovirus vector vaccine is made by using harmless modified adenovirus as a carrier and loaded into the virus' spike protein gene to stimulate the production of antibodies in the human body. It is safe, efficient, and causes few adverse reactions.
4) CONCLUSION On 9th Sept 2020, Bursa announced that HWGB BIOTECH SDB BHD had earmarked its production facilities by appointing XKX as a non-exclusive manufacture to produce vaccine.
XKX has the production facilities and is able to manufacture poliomyelitis vaccines, including different strains and formulation and dosage form systems of oral poliovirus (OPV), Oral Poliovirus (liquid) (OPVL) and Inactivated Poliovirus Vaccine (IPV) (“Polio Vaccines”) and the new indication which proposes the use of existing Polio Vaccines for prevention of COVID-19 virus (collectively “Vaccines”).
This was the last piece of the jigsaw puzzle to complete HWGB Biotech Sdn Bhd’s production & sales setup for EBI’s vaccine.
Should one invest in this vaccine production company now? You’ll be your own judge!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
mayongzheng
489 posts
Posted by mayongzheng > 2020-09-15 15:12 | Report Abuse
I Sell and buy back instantly just now!